Readers
Authors
Librarians
Editors
Reviewers
Advertisers/Sponsors
ISSN: 1877-282X
Imprint: ELSEVIER
Aims & Scope:
What is Procedia in Vaccinology?
Launched in 2009, Procedia in Vaccinology is an
e-only product focusing entirely on publishing high quality conference proceedings. Procedia in Vaccinology enables fast dissemination
so conference delegates can publish their papers in a dedicated online issue on ScienceDirect, ... click here for full Aims & Scope
Aims & Scope:
What is Procedia in Vaccinology?
Launched in 2009, Procedia in Vaccinology is an
e-only product focusing entirely on publishing high quality conference proceedings. Procedia in Vaccinology enables fast dissemination
so conference delegates can publish their papers in a dedicated online issue on ScienceDirect,
which is then made freely available worldwide.
Conference proceedings are accepted for publication in Procedia in Vaccinology
based on suitability and are required to meet certain criteria, including relevance to an international audience and covering highly
cited or timely topics. Procedia in Vaccinology will cover proceedings in all topics related to vaccines and vaccination.
What does Procedia in Vaccinology offer authors and conferences organizers?
Procedia in Vaccinology offers
a single, highly recognized platform where conference papers can be hosted and accessed by millions of researchers. Authors then know
where to go to keep abreast of the latest developments in their field. All proceedings appear online, on Science Direct, within 6 weeks
of acceptance of the final manuscripts via the conference organizer and are freely available to all users. Procedia in Vaccinology
offers authors and conference organizers a fast and cost effective way to provide maximum exposure for their papers.
Word templates
are provided to assist in the publication and the final online papers contain linked references, XML versions and DOI numbers. All papers
published in Procedia in Vaccinology are also be covered by Scopus.
Why should conference organizers choose Procedia in Vaccinology?
Unlike regular journals, there is no limit
to the amount of papers a Procedia in Vaccinology issue can contain and pricing is affordable, clear and transparent. Procedia
in Vaccinology offers immediate access for all, with papers online within 6 weeks of acceptance, and free access providing maximum
exposure for individual papers and the related conference. Organizers are be credited on the actual issue and are fully responsible for
quality control, the review process and the content of individual conference papers.
What is the process for submitting conference
proceedings to Procedia in Vaccinology?
Proposals, including a synopsis of why such a Procedia in Vaccinology
issue will have an impact on its community, a list of agreed contributors and an outline of the related conference (including a link
to the conference website) should be sent to:
Floris de Hon, PhD
Executive Publisher, Immunology & Microbiology
f.hon@elsevier.com
What are the costs associated with Procedia in Vaccinology?
There is an agreed fee, based on the size of the
proceedings, which includes online publication on ScienceDirect and
free access after acceptance. In addition to the online version there is the possibility to purchase paper copies, CD-ROMs and USB sticks.
Moreover, interactive media possibilities such as webcasts and web seminars can be acquired for extra exposure both before and after
the conference.
Can Procedia in Vaccinology? be sponsored?
We are open to discussing sponsoring possibilities
at all times. Sponsors can include funding bodies, government agencies and/or industry. Benefits to sponsors include visibility amongst
a scientific audience and the opportunity to communicate messages via a peer-reviewed platform. Benefits to authors and conference organizers
are the further dissemination of material to an international audience and reduced costs to the overall conference budget.
Hide Aims & Scope
This is a spacer...
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company